1.69
0.12 (7.64%)
| Previous Close | 1.57 |
| Open | 1.53 |
| Volume | 53,929 |
| Avg. Volume (3M) | 124,676 |
| Market Cap | 40,235,016 |
| Price / Sales | 0.160 |
| Price / Book | 2.05 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -72.72% |
| Operating Margin (TTM) | -124.00% |
| Diluted EPS (TTM) | -100.39 |
| Quarterly Revenue Growth (YOY) | 145.50% |
| Quarterly Earnings Growth (YOY) | -60.90% |
| Total Debt/Equity (MRQ) | 399.66% |
| Current Ratio (MRQ) | 0.190 |
| Operating Cash Flow (TTM) | -12.34 M |
| Levered Free Cash Flow (TTM) | -22.50 M |
| Return on Assets (TTM) | -17.45% |
| Return on Equity (TTM) | -147.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Celularity Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.83 |
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 55.61% |
| % Held by Institutions | 14.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| C V Starr & Co Inc | 31 Dec 2024 | 764,069 |
| Hb Wealth Management, Llc | 31 Mar 2025 | 40,763 |
| Biltmore Family Office, Llc | 31 Dec 2024 | 35,000 |
| Keynote Financial Services Llc | 31 Dec 2024 | 25,023 |
| Ipg Investment Advisors Llc | 31 Dec 2024 | 17,169 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 May 2025 | Announcement | Celularity Announces Full Year 2024 Operating and Financial Results |
| 25 Apr 2025 | Announcement | Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees |
| 14 Apr 2025 | Announcement | Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products |
| 07 Apr 2025 | Announcement | Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology |
| 25 Feb 2025 | Announcement | Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products |
| 24 Feb 2025 | Announcement | Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |